Immune Correlates of COVID-19 Control

COVID-19 caused by SARS CoV2 emerged in China at the end of 2019 and soon become a pandemic. Since the virus is novel, pre-existing CoV2-specific immunity is not expected to exist in humans, although studies have shown presence of CoV2 cross-reactive T cells in unexposed individuals. Lack of effecti...

Full description

Bibliographic Details
Main Authors: Bhawna Poonia, Shyam Kottilil
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.569611/full
id doaj-077f472b37e5482a923fa5f372638df9
record_format Article
spelling doaj-077f472b37e5482a923fa5f372638df92020-11-25T03:54:57ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-09-011110.3389/fimmu.2020.569611569611Immune Correlates of COVID-19 ControlBhawna PooniaShyam KottililCOVID-19 caused by SARS CoV2 emerged in China at the end of 2019 and soon become a pandemic. Since the virus is novel, pre-existing CoV2-specific immunity is not expected to exist in humans, although studies have shown presence of CoV2 cross-reactive T cells in unexposed individuals. Lack of effective immunity in most individuals along with high infectiousness of the virus has resulted in massive global public health emergency. Intense efforts are on to study viral pathogenesis and immune response to help guide prophylactic and therapeutic interventions as well as epidemiological assessments like transmission modeling. To develop an effective vaccine or biologic therapeutic, it is critical to understand the immune correlates of COVID-19 control. At the same time, whether immunity in recovered individuals is effective for preventing re-infection will be important for informing interventions like social distancing. Key questions that are being investigated regarding immune response in COVID-19 which will help these efforts include, investigations of immune response that distinguishes patients with severe versus mild infection or those that recover relative to those that succumb, durability of immunity in recovered patients and relevance of developed immunity in a cured patient for protection against re-infection as well as value of convalescent plasma from recovered patients as a potential therapeutic modality. This is a broad and rapidly evolving area and multiple reports on status of innate and adaptive immunity against SARS-CoV2 are emerging on a daily basis. While many questions remain unanswered for now, the purpose of this focused review is to summarize the current understanding regarding immune correlates of COVID-19 severity and resolution in order to assist researchers in the field to pursue new directions in prevention and control.https://www.frontiersin.org/article/10.3389/fimmu.2020.569611/fullCOVID-19 controlimmune correlates of COVID-19COVID-19 vaccineCOVID-19 immune therapySARS-CoV2 specific immunityCOVID-19 B cells
collection DOAJ
language English
format Article
sources DOAJ
author Bhawna Poonia
Shyam Kottilil
spellingShingle Bhawna Poonia
Shyam Kottilil
Immune Correlates of COVID-19 Control
Frontiers in Immunology
COVID-19 control
immune correlates of COVID-19
COVID-19 vaccine
COVID-19 immune therapy
SARS-CoV2 specific immunity
COVID-19 B cells
author_facet Bhawna Poonia
Shyam Kottilil
author_sort Bhawna Poonia
title Immune Correlates of COVID-19 Control
title_short Immune Correlates of COVID-19 Control
title_full Immune Correlates of COVID-19 Control
title_fullStr Immune Correlates of COVID-19 Control
title_full_unstemmed Immune Correlates of COVID-19 Control
title_sort immune correlates of covid-19 control
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2020-09-01
description COVID-19 caused by SARS CoV2 emerged in China at the end of 2019 and soon become a pandemic. Since the virus is novel, pre-existing CoV2-specific immunity is not expected to exist in humans, although studies have shown presence of CoV2 cross-reactive T cells in unexposed individuals. Lack of effective immunity in most individuals along with high infectiousness of the virus has resulted in massive global public health emergency. Intense efforts are on to study viral pathogenesis and immune response to help guide prophylactic and therapeutic interventions as well as epidemiological assessments like transmission modeling. To develop an effective vaccine or biologic therapeutic, it is critical to understand the immune correlates of COVID-19 control. At the same time, whether immunity in recovered individuals is effective for preventing re-infection will be important for informing interventions like social distancing. Key questions that are being investigated regarding immune response in COVID-19 which will help these efforts include, investigations of immune response that distinguishes patients with severe versus mild infection or those that recover relative to those that succumb, durability of immunity in recovered patients and relevance of developed immunity in a cured patient for protection against re-infection as well as value of convalescent plasma from recovered patients as a potential therapeutic modality. This is a broad and rapidly evolving area and multiple reports on status of innate and adaptive immunity against SARS-CoV2 are emerging on a daily basis. While many questions remain unanswered for now, the purpose of this focused review is to summarize the current understanding regarding immune correlates of COVID-19 severity and resolution in order to assist researchers in the field to pursue new directions in prevention and control.
topic COVID-19 control
immune correlates of COVID-19
COVID-19 vaccine
COVID-19 immune therapy
SARS-CoV2 specific immunity
COVID-19 B cells
url https://www.frontiersin.org/article/10.3389/fimmu.2020.569611/full
work_keys_str_mv AT bhawnapoonia immunecorrelatesofcovid19control
AT shyamkottilil immunecorrelatesofcovid19control
_version_ 1724471631714189312